866-997-4948(US-Canada Toll Free)

Metastatic Melanoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 403 Pages

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Melanoma Overview 11
Therapeutics Development 12
Pipeline Products for Metastatic Melanoma - Overview 12
Pipeline Products for Metastatic Melanoma - Comparative Analysis 13
Metastatic Melanoma - Therapeutics under Development by Companies 14
Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 20
Metastatic Melanoma - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Metastatic Melanoma - Products under Development by Companies 27
Metastatic Melanoma - Products under Investigation by Universities/Institutes 33
Metastatic Melanoma - Companies Involved in Therapeutics Development 34
Bristol-Myers Squibb Company 34
F. Hoffmann-La Roche Ltd. 35
Vical Incorporated 36
Amgen Inc. 37
Sanofi 38
AstraZeneca PLC 39
GlaxoSmithKline plc 40
Genentech, Inc. 41
MedImmune, LLC 42
Plexxikon Inc. 43
Delcath Systems, Inc. 44
Millennium Pharmaceuticals, Inc. 45
Novartis AG 46
Eisai Co., Ltd. 47
Ono Pharmaceutical Co., Ltd. 48
Pfizer Inc. 49
Celgene Corporation 50
Bayer AG 51
Incyte Corporation 52
Luitpold Pharmaceuticals, Inc. 53
Merck KGaA 54
Celldex Therapeutics, Inc. 55
Momenta Pharmaceuticals, Inc. 56
AVAX Technologies, Inc. 57
Oncolytics Biotech Inc. 58
Antisoma plc 59
Progen Pharmaceuticals Limited 60
HanAll Biopharma Co., Ltd. 61
Provectus Biopharmaceuticals, Inc. 62
BioAlliance Pharma SA 63
Scancell Holdings Plc 64
Morphotek, Inc. 65
DNA Therapeutics S.A. 66
Philogen S.p.A. 67
siRNAsense AS 68
Altor BioScience Corporation 69
Deciphera Pharmaceuticals, LLC 70
Affichem 71
Immutep S.A. 72
Polyphor Ltd. 73
Omeros Corporation 74
ImmuRx, Inc. 75
AB Science 76
CureTech Ltd. 77
WntResearch AB 78
Life Science Pharmaceuticals, Incorporated 79
Cancer Therapeutics CRC Pty Ltd 80
Cytavis Biopharma GmbH 81
n.v. BRUCELLS s.a. 82
California Stem Cell, Inc. 83
Lipotek Pty Ltd. 84
Immunophotonics Inc 85
OncoSec Medical Inc. 86
Vaxeal Holding SA 87
Bioncotech Therapeutics S.L. 88
AbbVie Inc. 89
Agalimmune Ltd 90
Metastatic Melanoma - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Target 93
Assessment by Mechanism of Action 101
Assessment by Route of Administration 110
Assessment by Molecule Type 113
Drug Profiles 116
trametinib dimethyl sulfoxide - Drug Profile 116
vemurafenib - Drug Profile 119
(dabrafenib + trametinib) - Drug Profile 122
melphalan - Drug Profile 124
velimogene aliplasmid - Drug Profile 126
vemurafenib - Drug Profile 128
paclitaxel albumin-bound - Drug Profile 131
talimogene laherparepvec - Drug Profile 133
M-Vax - Drug Profile 135
masitinib - Drug Profile 137
nivolumab - Drug Profile 139
cobimetinib + vemurafenib - Drug Profile 143
Contego - Drug Profile 145
Tumor Stem Cell Specific Dendritic Cell Therapy - Drug Profile 146
Cancer Stem Cell Therapy - Drug Profile 148
Modified Allogenic Melanoma Vaccine - Drug Profile 149
ipilimumab - Drug Profile 150
nilotinib - Drug Profile 153
sagopilone - Drug Profile 156
axitinib - Drug Profile 158
sunitinib malate - Drug Profile 161
Darleukin - Drug Profile 165
selumetinib sulfate - Drug Profile 167
pimasertib - Drug Profile 170
muparfostat - Drug Profile 172
pelareorep - Drug Profile 174
rose bengal sodium - Drug Profile 178
ontuxizumab - Drug Profile 180
ALT-801 - Drug Profile 182
pidilizumab - Drug Profile 184
AS-1409 - Drug Profile 186
aviscumine - Drug Profile 188
ecromeximab - Drug Profile 189
veliparib - Drug Profile 190
GSK-2132231A - Drug Profile 192
4-Peptide Melanoma Vaccine - Drug Profile 194
bevacizumab - Drug Profile 195
Anti-NY ESO-1 Lymphocytes Vaccine - Drug Profile 199
F5 TCR transgenic cells + MART-1 Peptide Pulsed Dendritic Cells - Drug Profile 200
Dendritic Cells Vaccine - Drug Profile 201
Anti-Mart-1 TCR-Gene Engineered Lymphocytes - Drug Profile 202
Dendritic Cell Vaccine - Drug Profile 203
DNA IL-12 - Drug Profile 204
MLN-2480 - Drug Profile 206
Contego - Drug Profile 208
NY-ESO-1 Targeted T cells - Drug Profile 209
Autologous Dendritic Cells Vaccine - Drug Profile 210
lenvatinib - Drug Profile 211
IMP-321 - Drug Profile 214
ARC-100 - Drug Profile 216
A-dmDT390-bisFv - Drug Profile 218
RAF-265 - Drug Profile 219
SCIB-1 - Drug Profile 220
BA-015 - Drug Profile 222
GSK-2302025A - Drug Profile 224
INCB-24360 - Drug Profile 225
ALT-803 - Drug Profile 227
Autologous T Cells Expressing Enhanced TCRs Specific For NY-ESO-1 and LAGE-1 - Drug Profile 229
metformin + [vemurafenib] - Drug Profile 231
MEDI-4736 - Drug Profile 232
Cell Therapy to Inhibit VEGFR-2 for Oncology - Drug Profile 233
trametinib + palbociclib - Drug Profile 234
pasireotide - Drug Profile 235
pevonedistat hydrochloride - Drug Profile 238
CDX-1127 - Drug Profile 240
LOC-paclitaxel - Drug Profile 241
Alpha-Gal Glycosphingolipids - Drug Profile 242
Cell Therapy to Inhibit MART-1, gp100, NY-ESO-1 and Tyrosinase for Metastatic Melanoma - Drug Profile 243
PLX-3397 - Drug Profile 244
Lipovaxin-MM - Drug Profile 246
rebastinib tosylate - Drug Profile 247
VLP Vaccine + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 249
GSK-2241658A - Drug Profile 250
GR-MD-02 - Drug Profile 251
RG-7446 - Drug Profile 253
RG-7636 - Drug Profile 255
AdVTMM2/DC + [interferon alfa-2b] - Drug Profile 256
SAR-260301 - Drug Profile 257
DT-01 - Drug Profile 258
interleukin-15 - Drug Profile 260
RG-7446 + vemurafenib - Drug Profile 262
M-402 - Drug Profile 263
AF-122 - Drug Profile 264
Box-5 - Drug Profile 265
HL-156Can - Drug Profile 266
DPK-M3 - Drug Profile 267
DPK-M1 - Drug Profile 268
BCL-005 - Drug Profile 269
inCVAX - Drug Profile 270
BO-110 - Drug Profile 272
MORAb-050 - Drug Profile 273
Recombinant IGFBP7 - Drug Profile 274
Tissue Factor Project - Drug Profile 275
austrasulfone - Drug Profile 276
SVX-1 Vaccine - Drug Profile 277
PRF-60077 - Drug Profile 278
POL-7085 - Drug Profile 279
Ceramide Analogs - Drug Profile 280
PC-113 - Drug Profile 281
HL-176 - Drug Profile 282
SAGEs for Cancer - Drug Profile 283
Anti-hCD-40 - Drug Profile 284
GPR19 Antagonist for Metastatic Melanoma - Drug Profile 285
FAK-FLT3-VEGFR3 Inhibitor Program - Drug Profile 286
miRNA-7-5p - Drug Profile 287
Endothelin Receptor Antagonist - Drug Profile 288
Saturated Lysophosphatidylcholine - Drug Profile 289
ZSG-101 - Drug Profile 290
ZSG-102 - Drug Profile 291
Riluzole Prodrug - Drug Profile 292
aldeluskin - Drug Profile 293
Metastatic Melanoma - Recent Pipeline Updates 294
Metastatic Melanoma - Dormant Projects 378
Metastatic Melanoma - Discontinued Products 386
Metastatic Melanoma - Product Development Milestones 387
Featured News & Press Releases 387

Appendix 394
Methodology 394
Coverage 394
Secondary Research 394
Primary Research 394
Expert Panel Validation 394
Contact Us 395
Disclaimer 395

List of Table


Number of Products under Development for Metastatic Melanoma, H1 2014 20
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Development by Companies, H1 2014 (Contd..3) 26
Number of Products under Development by Companies, H1 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 30
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Development, H1 2014 33
Comparative Analysis by Unknown Stage Development, H1 2014 34
Products under Development by Companies, H1 2014 35
Products under Development by Companies, H1 2014 (Contd..1) 36
Products under Development by Companies, H1 2014 (Contd..2) 37
Products under Development by Companies, H1 2014 (Contd..3) 38
Products under Development by Companies, H1 2014 (Contd..4) 39
Products under Development by Companies, H1 2014 (Contd..5) 40
Products under Investigation by Universities/Institutes, H1 2014 41
Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 42
Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 43
Metastatic Melanoma - Pipeline by Vical Incorporated, H1 2014 44
Metastatic Melanoma - Pipeline by Amgen Inc., H1 2014 45
Metastatic Melanoma - Pipeline by Sanofi, H1 2014 46
Metastatic Melanoma - Pipeline by AstraZeneca PLC, H1 2014 47
Metastatic Melanoma - Pipeline by GlaxoSmithKline plc, H1 2014 48
Metastatic Melanoma - Pipeline by Genentech, Inc., H1 2014 49
Metastatic Melanoma - Pipeline by MedImmune, LLC , H1 2014 50
Metastatic Melanoma - Pipeline by Plexxikon Inc., H1 2014 51
Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H1 2014 52
Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 53
Metastatic Melanoma - Pipeline by Novartis AG, H1 2014 54
Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H1 2014 55
Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 56
Metastatic Melanoma - Pipeline by Pfizer Inc., H1 2014 57
Metastatic Melanoma - Pipeline by Celgene Corporation, H1 2014 58
Metastatic Melanoma - Pipeline by Bayer AG, H1 2014 59
Metastatic Melanoma - Pipeline by Incyte Corporation., H1 2014 60
Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H1 2014 61
Metastatic Melanoma - Pipeline by Merck KGaA, H1 2014 62
Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2014 63
Metastatic Melanoma - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 64
Metastatic Melanoma - Pipeline by AVAX Technologies, Inc., H1 2014 65
Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H1 2014 66
Metastatic Melanoma - Pipeline by Antisoma plc, H1 2014 67
Metastatic Melanoma - Pipeline by Progen Pharmaceuticals Limited, H1 2014 68
Metastatic Melanoma - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 69
Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 70
Metastatic Melanoma - Pipeline by BioAlliance Pharma SA ,H1 2014 71
Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H1 2014 72
Metastatic Melanoma - Pipeline by Morphotek, Inc., H1 2014 73
Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H1 2014 74
Metastatic Melanoma - Pipeline by Philogen S.p.A., H1 2014 75
Metastatic Melanoma - Pipeline by siRNAsense AS, H1 2014 76
Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H1 2014 77
Metastatic Melanoma - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 78
Metastatic Melanoma - Pipeline by Affichem, H1 2014 79
Metastatic Melanoma - Pipeline by Immutep S.A., H1 2014 80
Metastatic Melanoma - Pipeline by Polyphor Ltd., H1 2014 81
Metastatic Melanoma - Pipeline by Omeros Corporation, H1 2014 82
Metastatic Melanoma - Pipeline by ImmuRx, Inc., H1 2014 83
Metastatic Melanoma - Pipeline by AB Science, H1 2014 84
Metastatic Melanoma - Pipeline by CureTech Ltd., H1 2014 85
Metastatic Melanoma - Pipeline by WntResearch AB, H1 2014 86
Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2014 87
Metastatic Melanoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 88
Metastatic Melanoma - Pipeline by Cytavis Biopharma GmbH, H1 2014 89
Metastatic Melanoma - Pipeline by n.v. BRUCELLS s.a., H1 2014 90
Metastatic Melanoma - Pipeline by California Stem Cell, Inc., H1 2014 91
Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H1 2014 92
Metastatic Melanoma - Pipeline by Immunophotonics Inc, H1 2014 93
Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H1 2014 94
Metastatic Melanoma - Pipeline by Vaxeal Holding SA, H1 2014 95
Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2014 96
Metastatic Melanoma - Pipeline by AbbVie Inc., H1 2014 97
Metastatic Melanoma - Pipeline by Agalimmune Ltd, H1 2014 98
Assessment by Monotherapy Products, H1 2014 99
Assessment by Combination Products, H1 2014 100
Number of Products by Stage and Target, H1 2014 103
Number of Products by Stage and Mechanism of Action, H1 2014 111
Number of Products by Stage and Route of Administration, H1 2014 120
Number of Products by Stage and Molecule Type, H1 2014 123
Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H1 2014 302
Metastatic Melanoma - Dormant Projects, H1 2014 386
Metastatic Melanoma - Dormant Projects (Contd..1), H1 2014 387
Metastatic Melanoma - Dormant Projects (Contd..2), H1 2014 388
Metastatic Melanoma - Dormant Projects (Contd..3), H1 2014 389
Metastatic Melanoma - Dormant Projects (Contd..4), H1 2014 390
Metastatic Melanoma - Dormant Projects (Contd..5), H1 2014 391
Metastatic Melanoma - Dormant Projects (Contd..6), H1 2014 392
Metastatic Melanoma - Dormant Projects (Contd..7), H1 2014 393
Metastatic Melanoma - Discontinued Products, H1 2014 394

List of Chart


Number of Products under Development for Metastatic Melanoma, H1 2014 20
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Products, H1 2014 33
Assessment by Monotherapy Products, H1 2014 99
Assessment by Combination Products, H1 2014 100
Number of Products by Top 10 Target, H1 2014 101
Number of Products by Stage and Top 10 Target, H1 2014 102
Number of Products by Top 10 Mechanism of Action, H1 2014 109
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 110
Number of Products by Top 10 Route of Administration, H1 2014 118
Number of Products by Stage and Top 10 Route of Administration, H1 2014 119
Number of Products by Top 10 Molecule Type, H1 2014 121
Number of Products by Stage and Top 10 Molecule Type, H1 2014 122

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *